Elevance Health shifts Carelon oversight to CFO Kaye as president Haytaian exits
Elevance Health announced management changes: CFO Mark Kaye will add oversight of Carelon, and Felicia Norwood will lead a consolidated Health Benefits organization. Carelon president Peter D. Haytaian leaves that role effective May 4, 2026, and will serve as Special Advisor through December 31, 2026. The company also reaffirmed its 2026 earnings and benefit expense ratio guidance, so the leadership changes come without a change to its outlook.
Key points
- Peter D. Haytaian leaves his role as President of Carelon effective May 4, 2026, to devote more time to family commitments; he will serve as Special Advisor through December 31, 2026.
- CFO Mark Kaye expands his responsibilities to include oversight of Carelon; Felicia Norwood assumes responsibility for the consolidated Health Benefits organization.
- 2026 guidance reaffirmed: shareholders' earnings of at least $22.30 per diluted share, including about $3.20 per diluted share of net unfavorable items; adjusted earnings of at least $25.50 per diluted share.
- Benefit expense ratio guidance for 2026 reaffirmed at 90.2% plus or minus 50 basis points.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.